Search

Author/Creator Ruff, Dustin

1. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies. Issue 9 (20th October 2018)

Authors:
Rosen, Noah; Pearlman, Eric; Ruff, Dustin; Day, Kathleen; Jim Nagy, Abraham
Journal:
Headache
Issue:
Volume 58:Issue 9(2018)
Page Start:
1347
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies. Issue 2 (21st November 2018)

Authors:
Nichols, Russell; Doty, Erin; Sacco, Sara; Ruff, Dustin; Pearlman, Eric; Aurora, Sheena K.
Journal:
Headache
Issue:
Volume 59:Issue 2(2019)
Page Start:
192
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN). (31st December 2022)

Authors:
Tobin, Joshua A.; Joshi, Shivang; Ford, Janet H.; Nichols, Russell M.; Foster, Shonda A.; Ruff, Dustin; Detke, Holland C.; Aurora, Sheena K.
Journal:
Journal of medical economics
Issue:
Volume 25:Number 1(2022)
Page Start:
1030
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗